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Abstract
Introduction: Inhaled corticosteroids (ICS) can interfere with 
the hypothalamic-pituitary-adrenal (HPA) axis and may lead 
to adrenal insufficiency, resulting in a decrease of cortisol 
production. Cortisol levels measured in scalp hair provide a 
marker for long-term cortisol exposure. Data regarding hair 
cortisol concentration (HCC) in asthmatic children with ICS 
therapy are scarce. The aim of this study is to compare HCC 
in asthmatic children under ICS treatment with a healthy 
control group. Methods: We set up a case-control study 
measuring the cortisol concentration in scalp hair in asth-
matic children (N = 80) treated with ICS and healthy controls 
(N = 252) aged 4–18 years. Anthropometric characteristics 
and hair samples from the posterior vertex were obtained. 
At least 5 mg of the most proximal 3 cm of hair was used for 
each hair sample. HCC was analyzed by liquid chromatogra-
phy-tandem mass spectrometry. Results: HCC did not sig-
nificantly differ between asthmatic children using ICS and 
healthy controls (p = 0.950) after adjustment for age, gender, 
height, body mass index, and socioeconomic status. No cor-
relation was found between budesonide dosage and HCC 
levels (r = –0.031, p = 0.78). Conclusion: There was no evi-
dence of suppression of basal cortisol production, as mea-
sured in scalp hair, in asthmatic children using ICS, com-
pared to healthy controls. No conclusions can be drawn on 
the HPA-axis stress response in these children.
© 2017 S. Karger AG, Basel
Introduction
Asthma is the most common chronic disease among 
children worldwide [1]. Inhaled corticosteroids (ICS) are 
the mainstays of treatment for persistent asthma in chil-
dren [2]. However, ICS can cause systemic side effects 
including suppression of the hypothalamic-pituitary-ad-
renal (HPA) axis with subsequent inability to produce a 
sufficient amount of cortisol [3, 4]. Cortisol is a glucocor-
ticoid stress hormone and is important for maintaining 
blood pressure, blood glucose, and energy levels during 
times of physiological stress (e.g., surgery or illness) [5]. 
A deficiency of cortisol can cause physical (e.g., fatigue, 
malaise, poor weight gain, or poor linear growth) and 
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symptoms of mental illness as manifested in Addison’s 
disease and is potentially life-threatening [6–8]. Clini-
cians are often aware of possible HPA-axis suppression 
that may occur in cases of long-term or high-dose ICS 
therapy [9, 10]. However, recent studies show that HPA-
axis suppression may already occur at low-to-moderate 
ICS doses [11, 12]. In clinical practice, screening for HPA-
axis suppression remains challenging since current tests 
fall short in several aspects. Cortisol measured in serum 
and saliva provides point estimates of HPA activity and is 
subject to the circadian rhythm and pulsatile secretion. 
Urinary measurements of cortisol may span up to 24 h 
and provide a rough estimate of cortisol levels over time. 
However, the collection of urine is often unpractical and 
unreliable [13, 14]. A more suitable, relatively new tech-
nique is to measure the long-term cortisol concentration 
in scalp hair [15, 16]. Previous data have shown that the 
measurement of hair cortisol successfully reflects endog-
enous cortisol levels [17, 18]. Assessment of the hair cor-
tisol concentration (HCC) has been validated, and in chil-
dren aged 4–18 years, reference ranges have been estab-
lished [19]. 
Studies regarding HCC in asthmatic children with ICS 
therapy are scarce [20, 21]. The aim of this case-control 
study was to compare long-term cortisol concentrations 
in scalp hair of asthmatic children receiving ICS treat-
ment with those of healthy children. Furthermore, we as-
sessed the association between ICS dosage and HCC in 
asthmatic children. 
Methods
The study was approved by the Medical Ethical Review 
Board. Written informed consent was obtained from parents 
and/or guardians and children when aged 12 years and older. 
Asthmatic children treated with ICS were recruited at the Groene 
Hart Hospital, a general hospital located in Gouda, The Nether-
lands, in a period of 3 months (May–July 2014). Asthmatic chil-
dren were eligible if they were (1) between 4 and 18 years old; 
(2) on ICS treatment for at least 3 months; (3) had a minimum 
of 3-cm-long scalp hair on the posterior vertex; (4) did not use 
systemic corticosteroids, and (5) were not hospitalized in the 
previous 3 months. Exclusion criteria comprised (1) other 
chronic diseases (e.g., eczema or anorexia nervosa), and/or (2) 
medication known to alter glucocorticoid metabolism (e.g., cor-
ticosteroids such as prednisone and hydrocortisone therapy). 
Healthy children were eligible as controls if they were, similar to 
the case group, (1) between 4 and 18 years old; (2) did not use 
glucocorticoids at the time of the study or in the previous 3 
months, and (3) did not have a chronic disease. Healthy controls 
were recruited from primary and secondary schools in the Neth-
erlands and among siblings of children attending the pediatric 
outpatient clinic.
Study Procedure 
Hospital records were used to identify asthmatic children treat-
ed with ICS who regularly attended the outpatient clinic. An invi-
tation to take part in the study and information regarding the study 
was sent to their home address. After informed consent had been 
retrieved, each child was included during his/her next visitation at 
the outpatient pediatric department. During this visit, a hair sam-
ple was collected, and the weight and height were measured. Body 
mass index (BMI) was calculated using the formula weight (kg)/
height (m2). Dosages, expressed in m2 of the body surface were 
calculated according to Mostellers’ formula [22]. Children were 
asked if their hair was dyed, bleached, or permed in the past 3 
months. Following local health care standards, all children had re-
ceived information on their asthma condition and training on the 
use of ICS and the required inhalation technique from a respira-
tory nurse specialist. The following data were obtained from med-
ical records: demographic data (i.e., gender, age, and socioeco-
nomic status [SES]) and ICS dose as prescribed by the treating 
physician. Healthy children were invited to take part in the study 
and received oral and written information. During school visita-
tion, a research nurse collected hair samples and measured the 
body weight and height. Further demographic information of the 
healthy controls, data on general health, the use of medication, and 
hair care were collected through a questionnaire. SES was deter-
mined by postal code, in accordance with the study by Knol et al. 
[23].
Hair Collection and Analysis of Cortisol in Hair
The hair sample (approx. 100–150 strands) was cut from the 
posterior vertex of the scalp as close to the scalp as possible. The 
posterior vertex has proven to display the lowest variance in corti-
sol concentration, potentially due to a more uniform growth rate 
[18]. The hair sample was taped to a piece of paper and stored at 
room temperature. The samples were sent to the laboratory of en-
docrinology of the Erasmus MC, Rotterdam, The Netherlands. At 
least 5 mg of the most proximal 3 cm of hair was weighed for each 
hair sample. The samples were then processed and analyzed as pre-
viously described [24]. The hair samples were cut into 1-cm pieces 
and washed in LC-MS grade isopropanol for 2 min. After solid 
phase extraction, hair cortisol was quantified by liquid chromatog-
raphy-tandem mass spectrometry (LCMS) using a Xevo TQ-S sys-
tem (Waters Chromatography, Milford, MA, USA).
Statistical Analysis
Statistical analyses were performed using SPSS 22.0 (IBM 
Corp., Armonk, NY, USA). Anthropometric standard deviation 
scores were calculated based on the 1997 Dutch nationwide growth 
study [25] using Growth Analyser RCT (Growth Analyser B.V., 
Rotterdam, The Netherlands). The Gaussian distribution of vari-
ables was assessed by the Kolmogorov-Smirnov test. Results are 
presented as the mean (95% confidence interval [CI]), median 
(range), and/or numbers (percentages). The ICS usage for each 
case was converted to a budesonide equivalent in µg/m2/day, were 
100 µg beclomethasone extra fine = 200 µg budesonide, 100 µg be-
clomethasone = 100 µg budesonide, and 100 µg fluticasone = 200 
µg budesonide. Univariable analyses were performed using the 
Student t test or Mann-Whitney U test for continuous variables 
(subject to the distribution of the respective variables) and the χ2 
test for categorical variables. Analyses of covariance was employed 
with HCC as the dependent variable and the case-control group as 
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the independent variable, while incorporating age, gender, BMI, 
height, and the SES score as potential confounders. The variables 
were log-transformed to achieve normality where needed. The 
Spearman correlation test was used to measure the relationship 
between the budesonide dose and HCC, with the significance lev-
el set at <0.05.
Results
In the 3 months study period, 237 asthmatic patients 
received an information letter, resulting in the inclusion 
of 86 cases. In the final statistical analyses, 1 child was ex-
cluded due to known inconsistent ICS usage, and 5 chil-
dren were excluded as a result of missing data on their 
HCC. All study subjects were outpatient children with 
mild-to-moderate asthma as defined by the Dutch asth-
ma guideline [26]. The median dose of budesonide in 
asthmatic children was 512.3 µg/m2/day (range: 180.7–
1,394.3) (Table 1). None were hospitalized (intensive 
care) or attended the emergency department during the 
study. Both cases and controls did not use steroid- 
containing ointments/creams for scalp usage. Asthmatic 
children were on average of lower height than healthy 
controls, and of less deprived areas in the Netherlands 
(i.e., had a lower SES score). Furthermore, the asthmatic 
children proved to have similar characteristics as our con-
trol group (Table 1). In the univariate analysis, the me-
dian HCC of asthmatic children (2.06 [range: 0.28–
20.65]) did not significantly differ from the HCC of 
healthy controls (2.22 [0.28–38.28], p = 0.805). After ad-
justment for age, gender, height, BMI, and SES score, 
again no sign of difference between the HCC of asthmat-
ic children and healthy controls was observed (p = 0.950). 
We assessed the correlation between the employed 
budesonide dosage and HCC and did not find that the 
amount of received treatment correlated with long-term 
cortisol concentrations measured in hair (r = –0.031, p = 
0.78; Fig. 1). 
Discussion
In this case-control study, we compared the long-term 
cortisol concentration in scalp hair (HCC) of asthmatic 
children receiving ICS with HCC in healthy children. Our 
main finding was that HCC levels in the former group did 
not significantly differ from that of healthy controls. As 
hair cortisol is considered an integrated measure of HPA 
activity over extended periods of time, this study did not 
find evidence for the suppression of cortisol production 
in asthmatic children using ICS. 
To our knowledge, this study comprises the first effort 
to compare HCC in a large group of asthmatic children 
treated with ICS. Two pilot case-control studies similar to 
the present study have been published [20, 21]. In con-
trast to our finding, Kamps et al. [20] concluded that 
HCC in asthmatic children treated with ICS (median 2.0 
pg/mg; 95% CI 1.4–4.1) was “significantly” lower than 
HCC in healthy children (4.3 pg/mg; 95% CI 1.8–5.9, p 
value not reported). Of note, while markedly different 
means are reported, the distribution of HCC of both the 
asthmatic and the control group completely overlap. 
Table 1. Baseline characteristics of the cases and healthy controls
Cases (N = 80) Healthy controls (N = 252) p value
Age, years 11.0 (4.1 to 17.6) 11.2 (4.3 to 18.0) 0.573
Male 40 (50) 126 (50) 1.000
Height for age, SDS –0.54 ± 1.3 0.21 ± 0.9 0.000*
Weight for age, SDS –0.23 ± 1.2 0.02 ± 0.8 0.088
BMI, SDS 0.12 –0.12 0.066
SES score 0.49 (–1.08 to 1.08) 0.93 (–4.96 to 2.36) 0.000*
Budesonide, µg/day 560 (200 to 1,200) – –
Budesonide, µg/m2/day 512.3 (180.7 to 1394.3) – –
Hair treatment (dyed), <3 months 1 (1.3) 5 (4.0) 0.352
Hair weight, mg 30.9 (20.4 to 36.8) 30.8 (15.4 to 34.6) 0.859
HCC, pg/mg 2.06 (0.28 to 20.65) 2.22 (0.28 to 38.28) 0.805
Values are mean ± standard deviation, n (%), or median (range). SDS, standard deviation score; BMI, body 
mass index; SES, socioeconomic status; HCC, hair cortisol concentration. SES, cases n = 79; SES, healthy controls 
n = 241; hair treatment (dyed), healthy controls n = 152. * Statistically significant (p < 0.05).
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Therefore, the clinical relevance of these results can be 
questioned. Moreover, due to the small sample size in 
both their study groups (n = 10), confounders were not 
corrected for. ICS dosage used by the asthmatic children 
was not reported, which hampers adequate comparison 
with our finding that budesonide dosage did not correlate 
with long-term HCCs. A second study by Smy et al. [21] 
also found that among 18 asthmatic children, HCC was 
significantly lower during ICS usage compared to a pe-
riod of no usage (median HCC of 89.8 ng/g [cases] vs. 
198.2 ng/g in the control group, p = 0.0015). The authors 
analyzed HCC using 2 measurements of hair strands 
from the same children, where each child comprised its 
own control. Enzyme-linked immunosorbent assay (ELI-
SA) was employed for the analysis, a test known to have 
low sensitivity when measuring in the lower ranges of 
cortisol concentration. In contrast to our study, children 
exposed to short courses of systemic corticosteroids or 
intranasal corticosteroids were not excluded. Moreover, 
the median age of asthmatic children was markedly 
younger (4 years, range 1.4–8.8). HCC levels have proven 
to be high and variable during infancy [27, 28]. Karlén et 
al. [27] found that HCC measured in healthy children of 
1 and 3 years of age proved to correlate with maternal 
cortisol levels during pregnancy but after periods of high 
variability were found to stabilize at older age (5 and 8 
years). This could imply that it is difficult to compare our 
study group with the children in Smy et al. [21]. Finally, 
as the authors conducted a pilot investigation, it lacked 
the statistical power to investigate dose-dependent differ-
ences in HCC. Further research is needed, in particular as 
other studies, though having used alternative measure-
ment techniques to scalp hair analysis, also report contra-
dicting findings [6, 12, 29].
Several studies identified HPA-axis suppression dur-
ing high ICS dosage in asthmatic children [30, 31], while 
others found an association between HPA suppression 
and lower ICS dosage [12, 32] or no association between 
ICS dosage and cortisol [33–36]. Despite these inconsis-
tencies, international guidelines have formulated a rec-
ommendation on when to measure cortisol during ICS 
therapy. In a recent guideline, ICS dosing categories in 
children >12 years are defined as low when ≤250 µg/day 
fluticasone propionate or equivalent is provided; me-
dium when a child receives 251–500 µg/day, and high 
at levels of >500 µg/day. In children aged 6–11 years, 
this is equivalent to ≤200, 201–400, and >400 µg/day. 
Screening for adrenal suppression is recommended in 
all children and adolescents receiving a high dose of ICS 
for 6 months or more; in children with symptoms sug-
gestive of insufficient amount of cortisol regardless of 
ICS dosage and/or in patients with factors that increase 
the systemic corticosteroid exposure [37]. Children in 
our study received 560 µg/day budesonide, equivalent 
to 280 µg/day fluticasone, i.e., subject to the age, a low-
to-medium dose. As such, our findings provide support 
for the referenced guidelines. However, we acknowl-
edge that in addition to the validation efforts from 
Noppe et al. [19], an extensive comparison between 
HCC and alternative matrices would be required before 
any conclusive clinical recommendations based on 
HCC can be provided. 
A strength of our study is that cortisol was measured 
over a prolonged period of time as we used scalp hair. 
Current non-stressed tests using serum, or saliva, repre-
sent an instantaneous secretion of cortisol and are sensi-
tive to the variance in cortisol related to its pulsatile secre-
tion and the circadian rhythm. HCC may be a robust way 
to study chronic suppression of cortisol production; how-
ever, one should note that no conclusions can be drawn 
on the HPA-axis acute stress response based on this met-
ric. Another strength of our study is that we used a sensi-
tive technique for the analysis, i.e., LCMS. Most studies 
on hair cortisol analyses employ ELISA, which, as men-
tioned before, performs poorly when measuring low cor-
tisol concentrations. LCMS has a proven higher sensitiv-
ity in smaller hair sample volumes, making the method 
more suitable for studying lower cortisol levels.
1,5000 250 500 750
Budesonide, µg/m2/day
1,000 1,250
15
10
H
CC
, p
g/
m
g
5
0
Fig. 1. Correlation between budesonide and hair cortisol concen-
tration (HCC). Spearman correlation r = –0.031, p = 0.78.
D
ow
nl
oa
de
d 
by
: 
Er
as
m
us
 U
ni
v.
of
 R
ot
te
rd
am
 M
ed
ica
l L
ib
ra
ry
   
   
   
   
  
14
5.
5.
87
.1
49
 - 
8/
31
/2
01
7 
10
:4
5:
46
 A
M
Scalp HCC in Asthmatic Children Using 
ICS
5Horm Res Paediatr
DOI: 10.1159/000478526
Our study has several limitations. We did not have 
information on ICS treatment adherence and the quality 
of the inhalation technique employed. Moreover, we did 
not have information on the exact duration of ICS ther-
apy, other than ICS being used for at least 3 months. As 
a result, the effective amount of ICS that was deposited 
in the lungs was uncertain. This may be an explanation 
for the absence of a correlation between HCC and ICS 
dosage in our study. However, all asthmatic children vis-
ited the respiratory nurse specialist on a 3-monthly basis 
to ensure appropriate usage and performance, and the 
majority of children used metered dose inhalers and 
spacers. Finally, 3 out of 80 patients had a markedly high 
HCC (>7.5 pg/mg). No clear differences in the measured 
characteristics of these patients compared to other cases 
were identified, and we have no clear explanation for 
these few outliers.
Conclusion
There was no evidence of suppression of basal cortisol 
production, as measured in scalp hair, in asthmatic chil-
dren using ICS, compared to healthy controls.
Nonetheless, clinicians should be aware of a potential 
HPA-axis suppression in asthmatic patients during ICS 
therapy regardless of the dose prescribed. Further re-
search is needed in asthmatic children with ICS therapy 
and a proven HPA-axis suppression to evaluate whether 
the measurement of cortisol in scalp hair is a useful tool 
for diagnosing adrenal insufficiency due to ICS in asth-
matic children. 
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